STAAR Surgical Past Earnings Performance
Past criteria checks 0/6
STAAR Surgical's earnings have been declining at an average annual rate of -57.6%, while the Medical Equipment industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-57.58%
Earnings growth rate
-57.37%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 6.47% |
| Return on equity | -23.37% |
| Net Margin | -33.60% |
| Next Earnings Update | 13 May 2026 |
Recent past performance updates
Recent updates
STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment
STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid
Apr 09
STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating
Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.
STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares
Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential
Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure
Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears
Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside
Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal
Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside
Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer
Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction
Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward
Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025
Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.Introduction Of EVO+ Will Open Market Opportunities In 2025
Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.Introduction Of EVO+ Will Open Market Opportunities In 2025
Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult
Jul 04
Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?
Apr 05Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge
Feb 14STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere
Feb 12STAAR Surgical: Growth Story Remains Intact Despite Some Challenges
Jan 31STAAR Surgical Company's (NASDAQ:STAA) Earnings Haven't Escaped The Attention Of Investors
Nov 29Return Trends At STAAR Surgical (NASDAQ:STAA) Aren't Appealing
Oct 24
EVO ICL Technology Transforms Vision Care, Securing Major Growth And Market Share Expansion
STAAR Surgical's record sales and expansion in the diopter curve indicate strong global adoption of EVO ICL technology and potential for increased market share.STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize
Sep 05Results: STAAR Surgical Company Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10STAAR Surgical Company's (NASDAQ:STAA) Popularity With Investors Is Clear
Aug 05The Returns At STAAR Surgical (NASDAQ:STAA) Aren't Growing
Jul 12Is There Now An Opportunity In STAAR Surgical Company (NASDAQ:STAA)?
May 27Market Participants Recognise STAAR Surgical Company's (NASDAQ:STAA) Revenues Pushing Shares 30% Higher
Apr 26STAAR Surgical Stock: I Don't See A Great Path Forward, Despite The Recent Surge
Apr 05Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How STAAR Surgical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 02 Jan 26 | 239 | -80 | 188 | 40 |
| 26 Sep 25 | 231 | -96 | 184 | 49 |
| 27 Jun 25 | 224 | -95 | 190 | 52 |
| 28 Mar 25 | 279 | -71 | 197 | 54 |
| 27 Dec 24 | 314 | -20 | 207 | 45 |
| 27 Sep 24 | 341 | 22 | 195 | 46 |
| 28 Jun 24 | 333 | 17 | 190 | 46 |
| 29 Mar 24 | 326 | 15 | 184 | 47 |
| 29 Dec 23 | 322 | 21 | 182 | 40 |
| 29 Sep 23 | 310 | 20 | 179 | 43 |
| 30 Jun 23 | 306 | 26 | 171 | 41 |
| 31 Mar 23 | 295 | 33 | 158 | 38 |
| 30 Dec 22 | 284 | 40 | 143 | 36 |
| 30 Sep 22 | 279 | 38 | 133 | 35 |
| 01 Jul 22 | 262 | 34 | 125 | 34 |
| 01 Apr 22 | 243 | 29 | 117 | 34 |
| 31 Dec 21 | 230 | 28 | 112 | 34 |
| 01 Oct 21 | 217 | 23 | 104 | 34 |
| 02 Jul 21 | 206 | 21 | 96 | 34 |
| 02 Apr 21 | 179 | 11 | 84 | 33 |
| 01 Jan 21 | 163 | 6 | 80 | 32 |
| 02 Oct 20 | 156 | 9 | 78 | 30 |
| 03 Jul 20 | 148 | 7 | 76 | 28 |
| 03 Apr 20 | 153 | 13 | 77 | 27 |
| 03 Jan 20 | 150 | 14 | 75 | 25 |
| 27 Sep 19 | 142 | 9 | 72 | 24 |
| 28 Jun 19 | 135 | 8 | 69 | 23 |
| 29 Mar 19 | 129 | 6 | 67 | 22 |
| 28 Dec 18 | 124 | 5 | 63 | 22 |
| 28 Sep 18 | 118 | 4 | 60 | 22 |
| 29 Jun 18 | 109 | 3 | 54 | 21 |
| 30 Mar 18 | 97 | 1 | 49 | 21 |
| 29 Dec 17 | 91 | -2 | 48 | 20 |
| 29 Sep 17 | 88 | -2 | 45 | 19 |
| 30 Jun 17 | 84 | -5 | 46 | 19 |
| 31 Mar 17 | 84 | -6 | 46 | 18 |
| 30 Dec 16 | 82 | -12 | 50 | 21 |
| 30 Sep 16 | 81 | -13 | 51 | 20 |
| 01 Jul 16 | 80 | -13 | 50 | 19 |
| 01 Apr 16 | 78 | -12 | 49 | 18 |
| 01 Jan 16 | 77 | -7 | 43 | 15 |
| 02 Oct 15 | 73 | -8 | 42 | 14 |
| 03 Jul 15 | 72 | -9 | 42 | 13 |
Quality Earnings: STAA is currently unprofitable.
Growing Profit Margin: STAA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STAA is unprofitable, and losses have increased over the past 5 years at a rate of 57.6% per year.
Accelerating Growth: Unable to compare STAA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STAA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (13.2%).
Return on Equity
High ROE: STAA has a negative Return on Equity (-23.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/05 22:40 |
| End of Day Share Price | 2026/05/05 00:00 |
| Earnings | 2026/01/02 |
| Annual Earnings | 2026/01/02 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STAAR Surgical Company is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |